Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 449, 393 (27 September 2007) | doi:10.1038/449393a; Published online 26 September 2007
Copycat consolidation
Meredith Wadman
Top of page
Abstract
As more blockbuster drugs come off patent, generic drugmakers face a changing landscape. Meredith Wadman looks at their strategies for survival.
One year ago, Mylan Laboratories was the world's ninth-largest generic drugmaker, a thoroughly American company with American clientele and American operations.Today, on the heels of two major acquisitions, the Pennsylvania-based company has vaulted into the ranks of the top three global generics players.
To read this story in full you will need to login or make a payment (see right).